Violations under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

Violations under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)

Such violations pertain to violations related to the manufacturing, processing, packing, or holding of drugs and pharmaceutical products. Violations falling under this category may include:

1. Failure to Follow Current Good Manufacturing Practices (cGMPs): This includes violations related to the failure to adhere to cGMP regulations, which outline the quality and safety standards for drug manufacturing.

2. Contamination Issues: Violations can occur if drugs are manufactured or stored in conditions that risk contamination with microorganisms, chemicals, or foreign substances that could compromise product safety and quality.

3. Inadequate Quality Control: This involves violations related to the inadequate implementation of quality control procedures, such as testing, to ensure the quality and consistency of drug products.

4. Lack of Proper Documentation: Violations may occur if there is insufficient or inaccurate documentation of manufacturing processes, batch records, quality control testing, or other critical aspects of drug production.

5. Mislabeling and Labeling Errors: This includes violations related to mislabeling drug products, inaccurate labeling, or issues with packaging and labeling that could lead to confusion or errors in drug administration.

6. Poor Record Keeping: Violations may occur if there is a lack of proper record keeping for critical manufacturing and quality control processes, making it difficult to trace the history of a drug product.

7. Inadequate Cleaning and Sanitation: Violations can result from inadequate cleaning and sanitation practices, potentially leading to cross-contamination or impurities in drug products.

8. Adulteration of Ingredients: Violations may involve the use of adulterated or substandard ingredients in drug manufacturing, leading to quality and safety concerns.

9. Environmental Control Issues: This includes violations related to inadequate environmental controls in manufacturing facilities, such as temperature and humidity control, which can impact product stability and quality.

10. Failure to Investigate and Address Deviations: Violations can occur when deviations from established procedures or specifications are not properly investigated, documented, or corrected.

11. Non-Compliance with Batch Requirements: Violations may involve the production of drug batches that do not meet established specifications, such as potency, purity, or dissolution requirements.

12. Inadequate Validation of Processes: Violations may occur if manufacturing processes are not properly validated to ensure their consistency and reliability.

13. Failure to Maintain Adequate Records of Complaints: Violations can result from the failure to adequately document and investigate complaints related to drug products.

14. Inadequate Testing for Product Identity, Strength, Purity, or Quality: Violations may involve the failure to conduct adequate testing to verify the identity, strength, purity, or quality of drug products.

15. Non-Compliance with Drug Master Files (DMFs): Violations can occur when a company fails to comply with DMF requirements for the submission of information on drug substances, excipients, and manufacturing processes.

It's important to note that these violations can have serious consequences, including regulatory actions, legal penalties, and potential harm to patient safety. Pharmaceutical companies must adhere to strict compliance with cGMP regulations and related requirements to ensure the quality, safety, and efficacy of their drug products.